Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the year-ago period. The growth was driven by approximately $11 million in net sales of TONMYA, the company's recently approved treatment for fibromyalgia. TONMYA recorded 12,592 total prescriptions during the quarter, up 100% sequentially, with new patient prescriptions increasing 36% and refills rising 207%. This commercial momentum underscores the market's acceptance of the first new fibromyalgia treatment in over 15 years.
The company also announced that TONMYA currently has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. Coverage is expected to expand to approximately 145 million lives when a managed Medicare agreement takes effect on January 1, 2027. This broad coverage is crucial for patient access and will likely drive further prescription growth.
In addition to commercial success, Tonix continues to advance its clinical pipeline. The company enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder. Furthermore, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These pipeline developments highlight Tonix's commitment to addressing high unmet medical needs in CNS and immunology.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial position provides a runway to support ongoing commercial efforts and clinical trials.
The strong quarterly performance and strategic pipeline progress position Tonix as a notable player in the biotechnology sector. The company's ability to generate significant revenue from TONMYA while advancing multiple clinical programs demonstrates its operational efficiency and potential for long-term growth. Investors and stakeholders will be watching closely as Tonix continues to execute on its commercial and clinical strategies.
